Skip to main content
Journal cover image

Phase II study of amonafide in advanced pancreatic adenocarcinoma.

Publication ,  Journal Article
Linke, K; Pazdur, R; Abbruzzese, JL; Ajani, JA; Winn, R; Bradof, JE; Daugherty, K; Levin, B
Published in: Invest New Drugs
November 1991

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Because of grade 4 myelosuppression observed in the initial 2 patients, the daily starting dose was decreased to 350 mg/m2. Of the 15 patients, 14 were evaluable. Amonafide failed to produce clinical responses in the doses and schedule employed. Grade 4 granulocytopenia was observed in 3 of 9 courses at 400 mg/m2, 3 of 12 courses at 350 mg/m2 and in 1 of 4 courses at 300 mg/m2. Grade 4 thrombocytopenia was observed in 3 courses at 400 mg/m2. Nonhematologic toxicities included mild nausea and vomiting and skin rashes.

Duke Scholars

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

November 1991

Volume

9

Issue

4

Start / End Page

353 / 356

Location

United States

Related Subject Headings

  • Pancreatic Neoplasms
  • Organophosphonates
  • Oncology & Carcinogenesis
  • Naphthalimides
  • Middle Aged
  • Male
  • Isoquinolines
  • Imides
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Linke, K., Pazdur, R., Abbruzzese, J. L., Ajani, J. A., Winn, R., Bradof, J. E., … Levin, B. (1991). Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs, 9(4), 353–356. https://doi.org/10.1007/BF00183580
Linke, K., R. Pazdur, J. L. Abbruzzese, J. A. Ajani, R. Winn, J. E. Bradof, K. Daugherty, and B. Levin. “Phase II study of amonafide in advanced pancreatic adenocarcinoma.Invest New Drugs 9, no. 4 (November 1991): 353–56. https://doi.org/10.1007/BF00183580.
Linke K, Pazdur R, Abbruzzese JL, Ajani JA, Winn R, Bradof JE, et al. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov;9(4):353–6.
Linke, K., et al. “Phase II study of amonafide in advanced pancreatic adenocarcinoma.Invest New Drugs, vol. 9, no. 4, Nov. 1991, pp. 353–56. Pubmed, doi:10.1007/BF00183580.
Linke K, Pazdur R, Abbruzzese JL, Ajani JA, Winn R, Bradof JE, Daugherty K, Levin B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs. 1991 Nov;9(4):353–356.
Journal cover image

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

November 1991

Volume

9

Issue

4

Start / End Page

353 / 356

Location

United States

Related Subject Headings

  • Pancreatic Neoplasms
  • Organophosphonates
  • Oncology & Carcinogenesis
  • Naphthalimides
  • Middle Aged
  • Male
  • Isoquinolines
  • Imides
  • Humans
  • Female